Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence